Botulinum Toxin A Detrusor Injections in Patients with Neurogenic Detrusor Overactivity Significantly Decrease the Incidence of Symptomatic Urinary Tract Infections

European Urology

Volumn 53, Issue 3, 2008, Pages 613-619

  Gamé, Xavier ^a   Castel Lacanal, Evelyne ^a   Bentaleb, Youssef ^a   Thiry Escudié, Isabelle ^a   De Boissezon, Xavier ^a   Malavaud, Bernard ^a   Marque, Philippe ^a   Rischmann, Pascal ^a  

^a CHU RANGUEIL   (France)

Author keywords

Botulinum toxin A; Neurogenic bladder; Neurourology; Urinary infection

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLADDER PRESSURE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MICTURITION CYSTOURETHROGRAPHY; MULTIPLE SCLEROSIS; MYELITIS; ORCHITIS; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; SPINAL CORD INJURY; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE CULTURE; URINE INCONTINENCE; URODYNAMICS;

ADULT; BOTULINUM TOXIN TYPE A; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE CONTRACTION; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 38749127218     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.039     Document Type: Article

References (31)

1. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
2. Schurch B., Schmid D.M., and Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342 (2000) 665
3. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 (2003) 165-174
4. Karsenty G., Corcos J., and Schurch B. Toxines botuliques: applications urologiques. Prog Urol 16 (2006) 263-274
5. Kalsi V., Apostolidis A., Popat R., et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535
6. Patel A.K., Patterson J.M., and Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50 (2006) 684-710
7. Esclarin De Ruz A., Garcia Leoni E., and Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 164 (2000) 1285-1289
8. Whiteneck G.G., Charlifue S.W., Frankel H.L., et al. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. Paraplegia 30 (1992) 617-630
9. De Sèze M., Ruffion A., Denys P., Joseph P.A., and Perrouin-Verbe B. Les vessies neurologiques et leurs complications dans la sclérose en plaques: revue de la littérature. Pelvi-périnéologie 1 (2006) 77-85
10. Soden R.J., Walsh J., Middleton J.W., et al. Causes of death after spinal cord injury. Spinal Cord 38 (2000) 604-610
11. Cardenas D.D., Hoffman J.M., Kirshblum S., and McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch Phys Med Rehabil 85 (2004) 1757-1763
12. Arnold E.P., and Cowan I.A. Clinical significance of ureteric diameter on intravenous urography after spinal cord injury. Br J Urol 62 (1988) 131-135
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
14. Ditunno Jr. J.F., Young W., Donovan W.H., and Creasey G. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 32 (1994) 70-80
15. Schafer W., Abrams P., Liao L., et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21 (2002) 261-274
16. Lose G., Griffiths D., Hosker G., et al. Standardisation of urethral pressure measurement: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 258-260
17. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
18. Reitz A., Stöhrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
19. Waites K.B., Canupp K.C., and DeVivo M.J. Epidemiology and risk factors for urinary tract infection following spinal cord injury. Arch Phys Med Rehabil 74 (1993) 691-695
20. Nicolle L.E. Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int J Antimicrob Agents 28 Suppl. 1 (2006) S42-S48
21. Yeo J.D., Walsh J., Rutkowski S., et al. Mortality following spinal cord injury. Spinal Cord 36 (1998) 329-336
22. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc 1992;15:194-204.
23. Kass E.H. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 69 (1956) 56-64
24. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 19 (2002) 592-597
25. Siroky M.B. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 113 Suppl. 1A (2002) 67S-79S
26. Kim Y.H., Bird E.T., Priebe M., and Boone T.B. The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol 158 (1997) 2083-2086
27. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;CD003193.
28. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;CD005429.
29. Denys P., Corcos J., Everaert K., et al. Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies. Curr Med Res Opin 22 (2006) 851-860
30. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
31. Sycha T., Samal D., Chizh B., et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 102 (2006) 509-516